financetom
Business
financetom
/
Business
/
Laurentian Bank Keeps Underperform, C$27 Target at National Bank
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Laurentian Bank Keeps Underperform, C$27 Target at National Bank
Feb 28, 2025 11:15 AM

01:50 PM EST, 02/28/2025 (MT Newswires) -- Laurentian Bank (LB.TO) has kept an Underperform rating, C$27 Target at National Bank in National's updated Q1 2025 earnings commentary.

LB reported Q1 2025 adjusted EPS of $0.78 versus a National Bank Financial forecast of $0.76 and consensus of $0.76.

Among key takeaways, National said LB reported a "good" Q1 2025, highlighted by a "favourable" loan growth mix that delivered stronger than expected margin performance. National does expect some margin reversion during Q2 2025 as some NIM factors were timing-related (i.e., not sustainable). It said expense growth is also expected to increase during Q2 2025, as the bank steps up investment initiatives. Finally, National is also increasing its PCL forecast next quarter, despite Q1 2025's in-line performance, to reflect a more conservative performing provision forecast. "We have applied this conservatism across the banking group this quarter in relation to economic uncertainty related to tariff potential," National added.

LB was at last look down 3.5% at $26.78.

Price: 26.76, Change: -0.99, Percent Change: -3.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Viking Therapeutics Reports 'Positive' 52-Week Results for NASH Drug; Shares Rise Pre-Bell
Viking Therapeutics Reports 'Positive' 52-Week Results for NASH Drug; Shares Rise Pre-Bell
Jun 4, 2024
08:30 AM EDT, 06/04/2024 (MT Newswires) -- Viking Therapeutics ( VKTX ) reported positive 52-week data from its phase 2b study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis, or NASH. The study showed significant reductions in liver fat and improvements in liver histology, the company said. VK2809-treated patients met secondary endpoints, showing higher rates of NASH resolution, fibrosis improvement,...
Joby Aviation Acquires Xwing's Autonomy Division
Joby Aviation Acquires Xwing's Autonomy Division
Jun 4, 2024
08:31 AM EDT, 06/04/2024 (MT Newswires) -- Joby Aviation ( JOBY ) said Tuesday it has acquired Xwing's autonomy division, boosting its ability to fulfill U.S. Department of Defense contracts and pursue future opportunities. The company said the deal was paid for with Joby shares, but other terms were not disclosed. Price: 4.8882, Change: +0.02, Percent Change: +0.37 ...
Aon Names Edmund Reese CFO
Aon Names Edmund Reese CFO
Jun 4, 2024
08:30 AM EDT, 06/04/2024 (MT Newswires) -- Aon (AON) said Tuesday that it has named Edmund Reese as its chief financial officer, effective July 29. The company said Reese will succeed Christa Davies, who will continue as a senior advisor until her retirement. Reese currently serves as the CFO of Broadridge Financial Solutions (BR), Aon said. ...
Broadridge Financial Solutions CFO Edmund Reese to Step Down to Become Aon CFO
Broadridge Financial Solutions CFO Edmund Reese to Step Down to Become Aon CFO
Jun 4, 2024
08:30 AM EDT, 06/04/2024 (MT Newswires) -- Broadridge Financial Solutions ( BR ) said Tuesday that Chief Financial Officer Edmund Reese will step down from his position on June 30 to become CFO of professional services firm Aon (AON). Broadridge said it has named Ashima Ghei, CFO of Broadridge's investor communication solutions segment, as interim CFO. The company said it...
Copyright 2023-2025 - www.financetom.com All Rights Reserved